In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that ...
The latest Zepbound data bodes well for Lilly and could help establish the drug as the new standard for obesity medications.
Eli Lilly plans a $3 billion expansion of its Wisconsin facility, creating 750 skilled jobs and boosting production capacity ...
Lilly's Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% ...
The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...
Eli Lilly LLY recently announced its plans to spend $3 billion to expand the manufacturing facility in Wisconsin that was ...
Research shows an average weight loss of just 5% could save an annual $153bn in medical fees and lost productivity.
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
After facing weeks of pushback, health insurer Anthem Blue Cross Blue Shield said it will not enact a policy change that ...
LLY's Zepbound shows better weight loss than NVO's Wegovy in a study. FDA updates for MRK, RHHBY, JNJ and AZN drugs grab ...
Job creation bounced back in November after disruptions from storms and a major strike, reinforcing a picture of modest expansion over the past few months. Everybody Loves FRED: How Americans Fell ...